Augustine Therapeutics N.V.

Plus: Management changes at Cidara, Fujifilm Cellular Dynamics and Transneural

VIB’s Jérôme van Biervliet says on The BioCentury Show that Europe needs to fulfill its long overdue mission in biotech as the U.S. enters uncertain terrain

Plus: Novo Holdings, Jeito lead week’s largest A round for VIB company Augustine — and more

Plus: Olazábal leaving Ysios and updates from Augustine and Prolific

Plus: New fundings for Exsilio, TwoStep and Augustine

Plus: Peter Flynn at the helm at Arialys, and updates from Augustine, CND, Parallel Bio and Zevra

Led by geneticist David Goldstein, the San Diego company thinks its ‘one-to-many’ strategy builds the economic case for going after very rare diseases